Pulford and collaborators showed the presence of autoantibodies against NPM1-ALK in ALCL patients [52], and higher antibody titers were correlated with improved overall and progression-free survival, as well as reduced relapse rates [53]. Here, NPM1 is linked to anaplastic large cell lymphoma.